Report Date: Thursday, July 30, 2026 (after market close) | Fiscal Period: 2026Q2
Ingersoll Rand reports second-quarter results tomorrow against a backdrop of a stock that has been volatile in 2026 — down from a February high near $99 to a May low near $68.50, before recovering to the mid-$80s heading into print (closed $84.63 on 7/29). The setup is a "show-me" quarter: management has repeatedly told investors that Q1 was the toughest print of the year and that margins and organic growth should inflect sequentially through 2026, with the bulk of the improvement weighted to the second half. Q2 is the bridge quarter — investors will be looking for proof that the recovery narrative is on track before the more decisive back-half acceleration.
Consensus for Q2: Adjusted EPS of roughly $0.80–$0.83 on revenue of about $1.96B (~3.8% growth), with Zacks noting an Earnings ESP of +0.61% and a track record of beating or meeting consensus in the trailing four quarters (average surprise +2.4%).
Ingersoll Rand's Q1 came in largely as expected, providing the baseline for this quarter's comparisons:
Management reaffirmed FY26 guidance on the Q1 call, which sets the framework investors will grade Q2 against:
Bottom line for Q2: Investors should expect roughly flat-to-slightly-positive organic revenue, EBITDA margin still down modestly year-over-year (concentrated in ITS), and full-year guidance likely reaffirmed rather than raised or cut, absent a major surprise.
Management has built a detailed bridge for why margins should improve from Q2 into 2H: volume flow-through as revenue improves, full lapping of 2025 tariff-driven pricing actions, normal-course pricing returning to a 1–2% run rate, restructuring benefits maturing, and direct-material productivity initiatives that are seasonally stronger in the back half. At the June Wells Fargo conference, CFO Vik Kini reiterated: "as we move to the first half of this year, you're kind of annualizing the tariff actions that were taken last year... there are in-year pricing actions that are being taken right now... that should lend itself to a slightly better pricing equation, price cost in the back half." Any signs that this bridge is slipping (e.g., commodity/tariff reacceleration, weaker-than-expected volume) would be a red flag.
Management has pointed to sequential improvement in short-cycle indicators — U.S. compressor stabilization, blower/vacuum strength, and core tools growing organically mid-single digits. On the Q1 call: "we saw progressive improvement, I would say, on the short-cycle through the quarter and kind of as we continue... moving into the month of April. But order cadence continues to go fairly well in terms of -- in line with expectations." Investors will want an update on whether this momentum continued through Q2 and into July.
The ~$40M of delayed Middle East orders was the standout Q1 talking point. Management indicated no expected impact on full year revenue or adjusted EBITDA and that a third of the delayed orders had already booked by April. Given continued geopolitical escalation in the region through July (oil price spikes, ongoing conflict headlines), watch for commentary on whether the remaining two-thirds of delayed orders came through in Q2, or whether the situation has worsened.
PST has been the relative bright spot — "Our Life Science business maintained robust growth with a double-digit increase in orders" in Q1, and Kini noted three consecutive quarters of PST segment EBITDA margins above 30%, with a medium-term target in the mid-30s. Continued double-digit growth in Life Sciences (particularly biopharma/ILC Dover) and sustained margin expansion here would support the segment's re-rating as a growth driver.
IR's inorganic growth engine remains central to the thesis: "Today, we have over 200 companies in our funnel with 10 transactions currently at the LOI stage. More than 90% of these opportunities remain internally sourced." The company also disclosed a pending deal north of $1B in the funnel (though not yet at LOI). Watch for updates on deal closings (e.g., Fox s.r.l., expected to close end of April) and progress toward the 400 to 500 basis points of annualized inorganic revenue target, as well as any commentary on the larger ~$1B+ transaction.
Broader trade-policy noise has intensified into late July — new Section 301 tariffs, Swiss tariffs, and legal challenges to the administration's tariff regime are all active. IR's own 10-Q flags this as an ongoing risk: "the current U.S. presidential administration has signaled its intention to implement significant changes to U.S. trade policy... these developments have not had a material impact on our financial condition or results of operations to date, due to their evolving nature... we cannot predict with certainty the ultimate impacts they may have on our business and results in the future, but those impacts could be material." Management's prior stance was that tariff/inflation nets out roughly neutral for 2026 — any change to that view would move the stock.
IR entered Q2 with ample flexibility: "With nearly $4 billion in total liquidity, our balance sheet remains a strategic asset... Our leverage remains well below 2x." As of Q1-end, the company had $2,600.0 million of unused availability under both the Revolving Credit Facility and Commercial Paper Program and was in compliance with all of our debt covenants. Capital priorities remain unchanged: M&A first, then buybacks and dividends.
IR shares have been on a wide round trip in 2026 — from ~$80 in January to a peak near $99 in early February, a slide to ~$68.50 by mid-May (post-Q1 disappointment on guidance optics and margin compression), and a recovery back to the mid-$80s over June–July as short-cycle data (ISM back above 50) and industrial sentiment broadly improved. The stock sold off sharply the day after Q1 earnings (from ~$84 to ~$77) despite an EPS beat, suggesting the market is highly sensitive to the margin trajectory and order/organic-growth commentary rather than the headline EPS number alone. Analyst price targets have generally clustered in the $90–$114 range, implying the market sees room for multiple expansion if the back-half acceleration proves out — but downside risk if commentary suggests further delays.
This preview is based on IR's 2026Q1 earnings call transcript, 2026Q1 10-Q, June 2026 Wells Fargo Industrials & Materials Conference transcript, recent market data, and sell-side commentary. All figures are as disclosed by the company or third-party sources cited above; actual Q2 results may differ materially.